|
Congestive heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Bio-adrenomedullin as a marker of congestion in patients with new-onset and worsening heart failure.
|
30843353 |
2019 |
|
Congestive heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Clinical value of pre-discharge bio-adrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission.
|
31797505 |
2019 |
|
Congestive heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Adrenomedullin in heart failure: pathophysiology and therapeutic application.
|
30592365 |
2019 |
|
Congestive heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Small-scale clinical trials have proven the efficacy and safety of recombinant AM peptide therapy for heart failure.
|
29577955 |
2019 |
|
Congestive heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
In addition to well-known vasoactive agents such as angiotensin II, endothelin, serotonin or natriuretic peptides, the vasoconstrictor Urotensin-II (Uro-II) and the vasodilators Urocortins (UCNs) and Adrenomedullin (AM) have been implicated in the control of vascular tone and blood pressure as well as in cardiovascular disease states including congestive heart failure, atherosclerosis, coronary artery disease, and pulmonary and systemic hypertension.
|
30481494 |
2019 |
|
Congestive heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
All molecular forms of AM are prognostic markers for heart failure.
|
29153200 |
2018 |
|
Congestive heart failure
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Based on these findings, it may be concluded that, compared with MSCs, MSCs overexpressing ADM can further improve heart function in rats experiencing heart failure through enhanced antifibrotic activity.
|
29138835 |
2018 |
|
Congestive heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Here, we compared its prognostic value for the occurrence of congestive heart failure with that of plasma mid-region pro-adrenomedullin (MR-proADM), a surrogate for adrenomedullin, a vasoactive peptide with vasodilator and natriuretic properties, in people with type 2 diabetes.
|
30232509 |
2018 |
|
Congestive heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Adrenomedullin (ADM) correlates with adverse cardiovascular outcomes in patients with acute myocardial infarction (AMI) and in patients with heart failure.
|
26766169 |
2017 |
|
Congestive heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
In this review, seven groups of biomarkers associated to myocardial stretch (mid-regional proatrial natriuretic peptide, MR-proANP), myocyte injury (high-sensitive troponins, hs-cTn; heart-type fatty acid-binding protein, H-FABP; glutathione transferase P1, GSTP1), matrix remodeling (galectin-3; soluble isoform of suppression of tumorigenicity 2, sST2), inflammation (growth differentiation factor-15, GDF-15), renal dysfunction (neutrophil gelatinase-associated lipocalin, NGAL; kidney injury molecule-1, KIM-1), neurohumoral activation (adrenomedullin, MR-proADM; copeptin), and oxidative stress (ceruloplasmin; myeloperoxidase, MPO; 8-hydroxy-2'-deoxyguanosine, 8-OHdG; thioredoxin 1, Trx1) in HF will be overviewed.
|
28212715 |
2017 |
|
Congestive heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Mid-regional pro-adrenomedullin and ST2 in heart failure: Contributions to diagnosis and prognosis.
|
28606358 |
2017 |
|
Congestive heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Second, this review explores other hormones that are augmented by sacubitril/valsartan such as bradykinin, substance P and adrenomedullin that may contribute to the efficacy of sacubitril/valsartan in HF.
|
28689178 |
2017 |
|
Congestive heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Receiver operating characteristic curves yielded an area under the curve of 1.00 (p<0.001) for UCN1, 1.00 (p<0.001) for ADM, and 0.99 (p<0.001) for pro-BNP in the diagnosis of HF.
|
25868038 |
2017 |
|
Congestive heart failure
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Significantly higher levels of ADM and IMD mRNA were found in CHF as a function of clinical severity (ADM: C=0.03 ± 0.013, NYHA I-II=0.11 ± 0.084, NYHA III-IV=11.46 ± 4.72, p=0.037 C vs NYHA III-IV, p=0.028 NYHA I-II vs NYHA III-IV; IMD: C=0.158 ± 0.041, NYHA I-II=0.93 ± 0.40, NYHA III-IV=2.6 ± 0.67, p=0.014 C vs NYHA III-IV, p=0.014 NYHA I-II vs NYHA III-IV).
|
24531032 |
2014 |
|
Congestive heart failure
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Further, plasma AM levels are increased in patients with various cardiovascular diseases, including hypertension, heart failure and renal failure.
|
16616959 |
2006 |
|
Congestive heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Increased plasma levels of adrenomedullin (ADM) have been reported in patients with congestive heart failure Immunohistochemical ADM has been identified in failing human ventricle, but the gene expression pattern of ADM messenger RNA (mRNA) in myocardial tissue of patients with heart failure has not been elucidated.
|
15539129 |
2004 |
|
Congestive heart failure
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Plasma levels of AM have now been shown to be increased in a number of pathological states, including congestive heart failure, sepsis, essential hypertension, acute myocardial infarction, and renal impairment.
|
15464589 |
2004 |
|
Congestive heart failure
|
0.300 |
Biomarker
|
disease |
RGD |
These results suggest that induction of the cardiac AM system, including the ligand, receptor, and amidating activity, may modulate pathophysiology during the transition from LVH to HF in this model.
|
12623952 |
2003 |
|
Congestive heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Altogether, the heart and the lungs release AM peptides in moderate CHF.
|
11972292 |
2002 |
|
Congestive heart failure
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
The actions of adrenomedullin and the activation of this peptide in cardiovascular disease suggest it may have an important pathophysiologic role in heart failure.
|
11305974 |
2001 |